

Hydreight Technologies Signs Binding Letter of Intent to Acquire Dynamic IV Therapy Support AI Agent

Not for distribution to United States newswire services or for dissemination in the United States.

Vancouver, British Columbia – September 8, 2025 - Hydreight Technologies Inc. (TSXV: NURS)(OTCQB: HYDTF)(FSE: SO6), (“**Hydreight**” or the “**Company**”), a North American, fully integrated, mobile clinical network of nurses, doctors, and pharmacy distribution, is pleased to announce that it has entered into a binding letter of intent dated September 5, 2025 (the “**LOI**”) with Auxano One LLC (“**Auxano**”), an arm’s length limited liability company based in Pennsylvania, in respect of a strategic asset acquisition and commercial relationship (the “**Transaction**”).

Pursuant to the LOI, the parties have agreed that:

- the Company would (a) acquire Auxano’s Dynamic IV Therapy Support AI Agent (the “**Target Asset**”) or (a) acquire the right to use the Target Asset (either, the “**Target Asset Acquisition**”);
- in exchange for the Target Asset Acquisition, Auxano will be entitled to the following consideration:
 - on closing (the “**Closing**”) of the Transaction, the Company will pay to Auxano US\$70,000 in cash,
 - upon the occurrence of a business milestone whereby the Target Asset is fully functional, integrated into the VSDHOne Platform and Hydreight App, and operational for intended use, and deliverable upon approval by the Company, the Company will issue 120,000 common shares in the capital of the Company (each, a “**Company Share**”) to Auxano,
 - upon the occurrence of a business milestone whereby US\$5,000,000 in revenue is generated in the aggregate for the Company and/or the VSDHOne by the Target Asset, the Company will issue 55,000 Company Shares to Auxano, and
 - Auxano will be entitled to certain revenue sharing rights in respect of the Target Asset as further described in the LOI; and
- the Company and Auxano will agree to a commercial relationship in respect of the Target Asset as further described in the LOI.

Shane Madden, CEO of Hydreight, commented: “We have been focused on developing and integrating artificial intelligence (AI) into our technologies across all three verticals, giving our customers powerful tools to create treatment plans for their patients. This not only enhances their ability to market services effectively but, more importantly, supports patients with long-term treatment planning. It’s an ideal addition to our ecosystem—tying together our pharmacies, technology platforms, and at-home testing solutions in a way that drives value for both providers and patients.”

Description of Target Asset

Dynamic IV Therapy Support AI Agent –An AI clinical assistant that analyzes patient health data (blood panels, genetic tests, health records) against standardized protocols to generate personalized IV therapy, supplements and preventative treatments recommendations. .

- Processes uploaded reports and electronic medical records data to suggest optimal IV drip formulations, nutrient concentrations, and complementary oral supplementation protocols.
- Ensures recommendations align with established standard operating procedures while providing clinical rationale, including contraindications and monitoring parameters.
- Streamlines treatment planning for providers while maintaining safety and efficacy standards.

Expanded Use Cases and Vertical Integration

While initially focused on IV therapy, the AI agent has broader applications across the health and wellness spectrum. By analyzing patient data such as blood panels, genetic testing, and medical history, the assistant could be adapted to support:

- **Hormone and longevity treatments** – optimizing personalized protocols for HRT, peptide therapies, and NAD.
- **Weight management programs** – enhancing GLP-1 and metabolic health solutions with precision treatment plans.
- **Preventative care and wellness** – integrating with at-home testing kits to provide insights on nutrition, supplementation, and lifestyle recommendations.

Integration Pathway

Through the VSDHOne platform, Hydreight plans to first integrate and scale the AI-driven assistant across its growing ecosystem of providers, pharmacies, and technology partners. VSDHOne serves as the Company's modular backbone, enabling new technologies to be deployed nationally and licensed to third parties. Over time, Hydreight believes this AI capability can be extended across its three core verticals, creating a unified data and intelligence layer for personalized healthcare delivery.

Market Opportunity

The opportunity for AI-powered clinical assistants extends well beyond IV therapy.

- **Healthcare AI & Clinical Decision Support**
The global AI in healthcare market was valued at approximately **US \$26.7 billion in 2024** and is expected to reach **US \$187 billion by 2030**, representing a CAGR of nearly **38%** ([Grand View Research](#), [The Research Insights](#)). More aggressive projections estimate the market could exceed **US \$500–700 billion by 2032–2034** ([Fortune Business Insights](#), [Market.us](#)). Clinical decision support systems—like the AI assistant Hydreight is integrating into VSDHOne—are among the fastest-growing use cases.
- **Wellness & Personalized Care**
Adjacent markets such as IV hydration therapy, hormone and longevity treatments, and weight management programs represent significant opportunities on their own. For example, the global IV hydration therapy market was valued at **US \$2.64 billion in 2024** and is projected to reach **US \$4.23 billion by 2030**, growing at a **CAGR of ~8%** ([Grand View Research](#)). Similarly, the broader intravenous therapy and vein access market is expected to grow from **US \$54.4 billion in 2023** to **US \$74.4 billion by 2029** ([BCC Research](#)).

By embedding this AI assistant into VSDHOne, Hydreight positions itself to serve both sides of the opportunity: the **explosive growth of AI in healthcare** and the **ongoing demand for personalized**

wellness solutions.

Jason Drohn, CEO of Auxano, said: “Hydreight is becoming a true all-in-one turnkey solution in this industry, and we are very excited to join forces with them, be part of their ecosystem, and support both their customers and patients.”

Details of the Transaction

The LOI contemplates that the parties will draft, finalize and execute a definitive agreement (a “**Definitive Agreement**”,) respecting the Transaction on or before November 4, 2025 (the “**Outside Date**”), with the option to mutually extend the Outside Date by an additional 30 days. The Transaction and the entering into of the Definitive Agreement are subject to mutual due diligence investigations. No finder’s fee will be paid in connection with the Transaction. The completion of the Transaction is subject to the fulfillment or waiver of several conditions, including receipt by Hydreight of approval from the TSX Venture Exchange, if required. The Transaction is expected to be structured as an “Expedited Acquisition” under the policies of the Exchange.

The Company Shares to be issued to Auxano in connection with the Transaction will be issued at a deemed price equal to the greater of CAD\$4.20 per share and the lowest price permitted by the policies of the Exchange and will be issued under prospectus exemptions pursuant to National Instrument 45-106 – *Prospectus Exemptions* of the Canadian Securities Administrators and in reliance upon exemptions from U.S. federal and state registration requirements and will be subject to a statutory hold period of four months in accordance with applicable Canadian securities laws and other hold periods in accordance with applicable U.S. securities laws and may bear legends to this effect.

The securities of the Company have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “**U.S. Securities Act**”) or any U.S. state securities laws and may not be offered or sold in the United States absent registration or an available exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referenced in this press release, in any jurisdiction in which such offer, solicitation or sale would be unlawful.

On behalf of the Board of Directors

Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.

Hydreight Technologies Inc Ranked Number 56 Fastest-Growing Company in North America on the [2024 Deloitte Technology Fast 500™](#)

Contact

Email: ir@hydreight.com; Telephone: 1 (702) 970-8112

About Hydreight Technologies Inc.

Hydreight Technologies Inc is building one of the largest mobile clinic networks in the United States. Its proprietary, fully integrated platform hosts a network of over 2500 nurses, over 100 doctors and a pharmacy network across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed

healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.

About VSDHOne - Direct to Consumer Platform

Developed in partnership with Victory Square Technologies (CSE: VST) (OTC: VSQTF) (FWB: 6F6), Hydreight launched the VSDHOne (Read as VSDH-One) platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s (semaglutide, tirzepatide), peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy (TRT), hair loss, skincare, sexual health and more. Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the online healthcare space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward Looking Information

This news release contains forward looking information or statements within the meaning of applicable securities laws, which may include, without limitation, statements relating to the terms and completion of the Transaction, including the entry into a Definitive Agreement, the receipt of corporate, regulatory and stock exchange approval in respect of the Transaction, the business prospects of the Company and Auxano, the perceived benefits of the Transaction and a commercial relationship between the Company and Auxano, and other matters. All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward looking information or statements. Although the Company believes the expectations expressed in such forward-looking information or statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking information or statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, the ability to achieve its goals, expected costs and timelines to achieve the Company's goals, that general business and economic conditions will not change in a material adverse manner, and that financing will be available if and when needed and on reasonable terms. Such forward looking information or statements reflects the Company's views with respect to future events and is subject to risks, uncertainties and assumptions, including the risks and uncertainties included in documents filed under the Company's profile on SEDAR+ at www.sedarplus.ca. While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive, and regulatory uncertainties and risks. Factors that could cause actual results to differ materially from those in forward looking information or statements include, but are not limited to, the ability of the Company to complete the Transaction on the terms described herein, including obtaining the requisite regulatory and stock exchange approvals, continued availability of capital and financing and general economic, market or business conditions, failure to compete effectively with competitors, failure to maintain or obtain all necessary permits, approvals and authorizations, failure to comply with applicable laws, including environmental laws, risks relating to unanticipated operational difficulties. The Company does not undertake to update forward looking statements or forward-looking information, except as required by law. All information contained in this news release regarding Auxano and its

subsidiaries was provided by its management team and Hydreight and its directors and officers have relied on Auxano for such information.